{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:23:45Z","timestamp":1769847825712,"version":"3.49.0"},"reference-count":16,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Cytomegalovirus (CMV) reactivations represent a significant morbidity and mortality problem in transplant patients. Reliable and rapid measurement of CMV viral load is a key issue for optimal patient management. We report here the evaluation of NeuMoDx\u2122 (Qiagen) in a routine hospital setting (University Hospitals of Marseille, France) in comparison with our classical reference technique R-GENE. During one month, 719 CMV viral loads from 507 patients were measured in parallel in both techniques. Using the ROC (receiver operating characteristic) curve and our biological experience we suggest that values &lt;52 IU\/mL (geometric mean) correspond to negative samples, values &gt;140 IU\/mL (Fowlkes\u2013Mallows index) correspond to quantifiable positive results and values ranging from 52 to 140 IU\/mL represent non-quantifiable positive results. Follow-up of 15 transplant patients who developed CMV reactivation during the study showed that NeuMoDx\u2122 provided higher viral load measurement during the first two weeks of follow-up for three patients. These important intra-individual variations resulted in a significant median increase considering the whole data set (6.7 points of difference expressed as a percentage of the initial viral load). However, no difference between the two techniques was noticeable after two weeks of treatment. Subsequent to this first study we conclude that NeuMoDx\u2122, used with optimized logistics and an adapted threshold, allows a rapid CMV viral load measurement and that its use does not lead to any difference in patient management compared to the reference technique R-GENE\u00ae.<\/jats:p>","DOI":"10.3390\/v13081619","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T21:28:04Z","timestamp":1629149284000},"page":"1619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytomegalovirus Viral Load in Transplanted Patients Using the NeuMoDx\u2122 (Qiagen) Automated System: A 1-Month Experience Feedback"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-5957","authenticated-orcid":false,"given":"L\u00e9a","family":"Luciani","sequence":"first","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Aix-Marseille Universit\u00e9, IRD 190-Inserm 1207, 13005 Marseille, France"},{"name":"Laboratoire de Microbiologie, Assistance Publique-H\u00f4pitaux de Marseille, IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-8395","authenticated-orcid":false,"given":"Denis","family":"Mongin","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Gen\u00e8ve, 1205 Gen\u00e8ve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Ninove","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Aix-Marseille Universit\u00e9, IRD 190-Inserm 1207, 13005 Marseille, France"},{"name":"Laboratoire de Microbiologie, Assistance Publique-H\u00f4pitaux de Marseille, IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Nougair\u00e8de","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Aix-Marseille Universit\u00e9, IRD 190-Inserm 1207, 13005 Marseille, France"},{"name":"Laboratoire de Microbiologie, Assistance Publique-H\u00f4pitaux de Marseille, IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Bardy","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie, Assistance Publique-H\u00f4pitaux de Marseille, IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Gazin","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie, Assistance Publique-H\u00f4pitaux de Marseille, IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7675-8251","authenticated-orcid":false,"given":"Remi N.","family":"Charrel","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Aix-Marseille Universit\u00e9, IRD 190-Inserm 1207, 13005 Marseille, France"},{"name":"Laboratoire de Microbiologie, Assistance Publique-H\u00f4pitaux de Marseille, IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"},{"name":"Comit\u00e9 de Lutte Contre les Infections Nosocomiales, H\u00f4pitaux Universitaires de Marseille (AP-HM), 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Zandotti","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (UVE), Aix-Marseille Universit\u00e9, IRD 190-Inserm 1207, 13005 Marseille, France"},{"name":"Laboratoire de Microbiologie, Assistance Publique-H\u00f4pitaux de Marseille, IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"},{"name":"Comit\u00e9 de Lutte Contre les Infections Nosocomiales, H\u00f4pitaux Universitaires de Marseille (AP-HM), 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0163-7258(03)00034-2","article-title":"The Human Cytomegalovirus","volume":"98","author":"Landolfo","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"ref_2","unstructured":"Boucher, C.A.B., Galasso, G.A., Katzenstein, D.A., and Cooper, D.A. (2002). Chapter 7\u2014Cytomegalovirus. Practical Guidelines in Antiviral Therapy, Elsevier."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"ref_4","first-page":"113","article-title":"Cytomegalovirus Infection in Patients with HIV Infection","volume":"66","author":"Tw","year":"1999","journal-title":"Mt. Sinai J. Med. N. Y."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/ajhp\/zxaa183","article-title":"Cytomegalovirus Esophagitis in a Patient on Ocrelizumab Therapy: A Case Report","volume":"77","author":"Miller","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00043-19","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","first-page":"307","article-title":"Measurement in Medicine: The Analysis of Method Comparison Studies","volume":"32","author":"Altman","year":"1983","journal-title":"J. R. Stat. Soc. Ser. Stat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/CIRCULATIONAHA.105.594929","article-title":"Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models","volume":"115","author":"Zou","year":"2007","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jviromet.2007.06.013","article-title":"Multicentric Evaluation of a New Commercial Cytomegalovirus Real-Time PCR Quantitation Assay","volume":"146","author":"Gouarin","year":"2007","journal-title":"J. Virol. Methods"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"German, D.M., Adams, B., and Hassan, A.E. (2013, January 5\u20138). The Evolution of the R Software Ecosystem. Proceedings of the 2013 17th European Conference on Software Maintenance and Reengineering, Genova, Italy.","DOI":"10.1109\/CSMR.2013.33"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of Viral-Load Kinetics to Identify Patients Who Develop Cytomegalovirus Disease after Transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/01621459.1983.10478008","article-title":"A Method for Comparing Two Hierarchical Clusterings","volume":"78","author":"Fowlkes","year":"1983","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/TP.0000000000000189","article-title":"A Double-Blinded, Prospective Study to Define Antigenemia and Quantitative Real-Time Polymerase Chain Reaction Cutoffs to Start Preemptive Therapy in Low-Risk, Seropositive, Renal Transplanted Recipients","volume":"98","author":"Triboni","year":"2014","journal-title":"Transplantation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","article-title":"Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients","volume":"101","author":"Natori","year":"2017","journal-title":"Transplantation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e01044-17","DOI":"10.1128\/AAC.01044-17","article-title":"Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes","volume":"61","author":"Piret","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:47:11Z","timestamp":1760165231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081619"],"URL":"https:\/\/doi.org\/10.3390\/v13081619","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]}}}